<DOC>
	<DOCNO>NCT01229215</DOCNO>
	<brief_summary>This Phase Ib/II , multicenter , randomize , single-masked , sham-injection-controlled study safety , tolerability , evidence activity FCFD4514S intravitreal injection administer monthly every month patient geographic atrophy .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Evidence Activity FCFD4514S Administered Monthly Every Other Month Patients With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Willingness ability provide sign Informed Consent ; addition , U.S. sit , Health Insurance Portability Accountability Act ( HIPAA ) authorization , country , applicable accord national law Welldemarcated area GA secondary agerelated macular degeneration ( AMD ) absence choroidal neovascularization ( CNV ) History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation study eye Prior treatment Visudyne , externalbeam radiation therapy , transpupillary thermotherapy study eye GA either eye due cause AMD Diabetic retinopathy either eye Active history wet AMD either eye History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Active malignancy history malignancy within past 5 year Previous participation study investigational drug within 3 month precede Day 0</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>